Dizal (Jiangsu) Pharmaceutical (SHA:688192) presented the efficacy results of its DZD8586 drug for B-cell non-Hodgkin lymphoma during a meeting of the American Society of Hematology.
The drug is indicated to hurdle Bruton's tyrosine kinase resistance mutations and is effective against tumors, according to a Tuesday filing with the Shanghai Stock Exchange.
B-cell non-Hodgkin lymphoma targets the body's lymphatic system and is a malignant cancer prone to relapse following treatment, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.